Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ATLAS Trial Design Blamed For Missing Data On Xarelto ACS Use

Jun 04 2012

• By Sue Sutter

Related Content

Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Nov 07 2011

<em>Xarelto</em> Acute Coronary Syndromes Claim Faces Data Quality Hurdle

May 22 2012

ATLAS Data Not Strong Enough To Support <em>Xarelto</em>’s Use In ACS, FDA Panel Says

May 28 2012

FDA Panel Looks Beyond <em>Xarelto</em>’s Missing Data Problems To Broader Reforms

Jun 04 2012

ROCKET AF’s Design Causes Headaches For <i>Xarelto</i> Sponsors

Sep 19 2011

Related Companies

Johnson & Johnson

Bayer AG

Johnson & Johnson

Additional Topics

Advisory Committees Clinical Trials Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window